Analysis of the Clinical Trial for Cancer Pain Drugs Based on the Clinical Trials Database
10.3870/j.issn.1004-0781.2024.10.018
- VernacularTitle:基于Clinical Trials数据库的癌性疼痛治疗药物临床试验分析
- Author:
Zhaoqun CHU
1
;
Jingwen MA
;
Tianze SHANG
;
Zaoqin YU
;
Guangzhao HE
;
Chencheng WANG
Author Information
1. 南京大学医学院附属鼓楼医院科技处,南京 210008
- Keywords:
Drug clinical trial;
Cancer pain;
Investigator-initiated trials;
Industry-sponsored trials
- From:
Herald of Medicine
2024;43(10):1640-1645
- CountryChina
- Language:Chinese
-
Abstract:
Objective To understand the trends and characteristics of clinical trials on cancer pain medications in recent years,and to provide a reference basis for the development and clinical research of cancer pain medications.Methods Relevant information on clinical trials of cancer pain medications from 1987 to 2022 was retrieved from the ClinicalTrials.gov database,and a descriptive analysis was conducted from the perspectives of trial types,registration dates,reporting regions,cancer pain type,and cancer pain medications.Results A total of 376 clinical trials were selected,Among them,the number of investigator-initiated trials(IIT)was greater than that of industry-sponsored trials(IST).North America had the highest total number of projects,IIT and IST projects.The total number of trials and IST projects increased first and then decreased,while the number of IIT trials steadily increased.There was relatively higher amount nof research focused on chronic cancer pain,breakthrough cancer pain,and severe cancer pain.The highest proportion of subjects studied were opioids,with fentanyl being particularly prominent among them.Conclusion Clinical trials of cancer pain medications have played an important role in advancing cancer pain medication,but there is a need to further strengthen IST research on novel cancer pain medications and conduct more IIT studies to better optimize cancer pain treatment outcomes.
